Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Next Previous
X
Search
Trial Profile

CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VE 303 (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONSORTIUM
  • Sponsors Vedanta Biosciences

    • Most Recent Events

    • 16 Oct 2024 Results presented in the Vedanta Biosciences Media Release.
    • 16 Oct 2024 According to a Vedanta Biosciences media release, the results from this study were published in the Journal of the American Medical Association in 2023.
    • 16 Oct 2024 According to a Vedanta Biosciences media release, company to present data from this study in an oral presentation at Infectious Diseases Week (IDWeek), Friday October 18, in Los Angeles, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top